Feasibility study on the implementation of the new prostate cancer screening recommendation in Germany: PSA measurement using capillary blood sampling (PRO-KAP)

Feasibility study on the implementation of the new prostate cancer screening recommendation in Germany: PSA measurement using capillary blood sampling (PRO-KAP) - PRO-KAP

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00039494

Enrollment

200

Registered

2026-03-05

Start date

2026-03-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Men aged 49-51 years from the study region Heidelberg are invited for a PSA measurement using capillary blood at the prevention outpatient clinic of the National Cancer Prevention Center (NCP

Eligibility

Sex/Gender

Male

Age

49 Years to 51 Years

Inclusion criteria

Inclusion criteria: living in the study region Heidelberg; receipt of invitation letter

Exclusion criteria

Exclusion criteria: previous diagnosis of prostate cancer; biopsy of the prostate within 6 months prior to the invititation

Design outcomes

Primary

Measure	Time frame
Acceptance of PSA-based early detection (percentage of men who participate in the study out of the total of contacted men)	—

Secondary

Measure	Time frame
- Identification of factors promoting and barriers to the implementation of capillary blood sampling at the NCPC as a new access route for a prostate cancer screening programme - Evaluation of reasons for and against participation	—

Countries

Germany

Contacts

Public ContactPetra Seibold

Deutsches Krebsforschungszentrum (DKFZ)

p.seibold@dkfz.de+49 6221 42 2208

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026